Thomas Smeenk Discusses the Intersection of Hemostemix’s NCP Treatment and Elon Musk’s Neuralink

In this InvestorIntel interview, Tracy Weslosky talks with Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, CEO, and President Thomas Smeenk about the significance of engaging Dr. Chris McNorgan, Ph.D., to drive a license agreement of NCP-01 (Neural Cellular Precursors) with a neural electrode brain implant company.

Dr. McNorgan directs the Computational Cognitive Neuroscience (CCN) laboratory at the University of Buffalo and his research – the neural bases of cognition, including AI methods to decode and simulate neocortical representations of knowledge and motor intention – is directly relatable to neural electrode-based implantation.

With Dr. McNorgan’s appointment, it brings another expert onto the team that includes Dr. Henderson, a neurosurgeon, and Dr. Inna Sorel, the mother of the invention of NCP itself, to help drive the legitimacy of licensing the NCP-01 platform. Thomas discusses the potential for licensing and partnerships to take NCP-01 to the neural electrode-based implantation market, an industry that is being led by players such as Elon Musk’s Neuralink.

NCP is a neuronal cell precursor generated from a patient’s own blood, which homes to the site of injury and regenerates the site of injury on a neuronal cell basis. Thomas explains how Hemostemix’s NCP-01 has the potential to regenerate injured neuronal cells to support the implantations of electrodes. Thomas also discusses a pre-clinical study conducted in animals using Hemostemix’s NCP-01 that showed positive results with more than 90% of the NCP color-coded cells ending up at the site of stroke, embedding at the site, and regenerating neuronal factors that would repair the site of a stroke.

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursors, and cardiomyocyte cell precursors.

To learn more about Hemostemix Inc., click here

Disclaimer: Hemostemix Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].

Disclaimer: The author of this Investor.News post, which is published by InvestorNews Inc., may or may not be a shareholder of any of the companies mentioned in this column. No company mentioned has sponsored or paid for this content on Investor.News, and InvestorNews Inc. does not accept opt-in payments from advertisers. While InvestorNews Inc. provides digital media services like video interviews and podcasts to advertisers, not all are paid promotions. Any sponsored video interview will be clearly marked in the summary. The author of this piece is not a licensed investment advisor and makes no recommendations to buy, sell, or hold any securities. If the author holds an investment advisor license, this will be stated in their biography. Conduct your own due diligence by reviewing public documents of any company. For our full legal notices and disclaimers, click here click here.

Leave a Reply

Your email address will not be published. Required fields are marked *